Financial Performance - The company's operating revenue for the first half of 2023 was ¥190,050,700.64, representing a 22.35% increase compared to ¥155,329,759.94 in the same period last year[24]. - The net profit attributable to shareholders decreased by 44.76% to ¥6,382,540.84 from ¥11,554,184.55 year-on-year[24]. - Basic earnings per share fell by 44.61% to ¥0.0267 from ¥0.0482 in the same period last year[24]. - The company reported a decrease of 28.95% in net profit after deducting non-recurring gains and losses, amounting to ¥3,549,187.89 compared to ¥4,995,227.47 last year[24]. - The weighted average return on net assets decreased to 0.91% from 1.68% year-on-year[24]. - The company reported a total investment of 195.87 million yuan for the annual production of 400 million bottles of Gu Han Yang Sheng oral liquid, with 100 million yuan funded by raised capital[64]. - The company reported a net loss improved to CNY -54,583,126.10 from CNY -60,965,666.94, indicating a reduction in losses[129]. - The company's net profit for the first half of 2023 was reported at 45.89 million yuan, compared to a loss of 116.9 million yuan in the same period last year, indicating a turnaround in profitability[158]. Cash Flow and Investments - The net cash flow from operating activities turned negative at -¥40,029,572.99, a decline of 190.65% compared to ¥44,160,594.59 in the previous year[24]. - The company's cash flow from operating activities showed a net outflow of ¥40,029,572.99, a decrease of 190.65% compared to the previous year[44]. - The net cash flow from investment activities was 17,511,220.15 yuan, a decrease of 28.3% from 24,400,626.06 yuan in the first half of 2022[143]. - The net cash flow from financing activities was -13,883,512.64 yuan, compared to a positive cash flow of 1,142,827.80 yuan in the same period of 2022[143]. - The total cash and cash equivalents at the end of the period were 198,411,359.21 yuan, down 37.2% from 316,065,329.07 yuan at the end of the first half of 2022[143]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,124,199,451.52, down 3.65% from ¥1,166,753,854.92 at the end of the previous year[24]. - The total liabilities decreased to CNY 415,432,073.81 from CNY 464,259,983.71, indicating a reduction of 10.5%[129]. - The company's total equity increased to CNY 708,767,377.71 from CNY 702,493,871.21, reflecting a growth of 0.4%[129]. - The company's accounts receivable amounted to RMB 79,912,406.66 at the end of the reporting period, reflecting a change in collection efficiency[51]. - The total number of shares outstanding is 239,471,267, with 99.96% being unrestricted shares[112]. Research and Development - Research and development investment rose by 14.31% to ¥6,093,258.48, reflecting the company's commitment to innovation[44]. - The company is advancing its research and development efforts, including the approval of national standards for its key products and the establishment of a digital transformation initiative to enhance operational efficiency[37]. - Research and development expenditures have increased by 5.7% compared to the previous period, indicating a focus on innovation[152]. Market and Sales Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese and Western medicine, with a strong brand presence and product variety, making it one of the major pharmaceutical enterprises in Hunan Province[32]. - The company has implemented a dual sales model, utilizing both agency distribution and direct supply to enhance market reach and control over product flow, particularly for medical insurance products[34]. - In the first half of the year, the company optimized its sales structure and enhanced brand promotion, resulting in improved market share and sales performance through innovative marketing strategies[35]. - The company aims to leverage its unique advantages in traditional Chinese medicine to capitalize on the growing health awareness among consumers, driven by demographic changes and economic development[32]. - The company is actively exploring new growth opportunities through e-commerce and expanding its product line to meet diverse consumer needs[35]. Environmental Compliance - The environmental protection license for the traditional Chinese medicine company is valid from May 28, 2023, to May 27, 2028[83]. - The company has reported that it complies with various environmental standards, including the "Comprehensive Emission Standard of Air Pollutants" and "Water Pollutants Discharge Standard for Pharmaceutical Industry"[83]. - The company achieved a wastewater treatment efficiency of 98% and a waste gas pollutant removal efficiency of 90% with its environmental facilities[85]. Shareholder Information - The annual shareholders' meeting had a participation rate of 46.27% on May 18, 2023[77]. - The company plans not to distribute cash dividends or issue bonus shares for the first half of 2023[79]. - The largest shareholder, Tsinghua Technology Service Limited, holds 29.41% of shares, totaling 70,432,904 shares, which are frozen[114]. Risk Management - The company has outlined potential risks and countermeasures in its management discussion section, which investors are encouraged to review[4]. - The company faces risks related to product structure concentration, with a high dependency on the "Gu Han Yang Sheng Jing" series[72]. - The company is implementing measures to control raw material price fluctuations, including strategic procurement and inventory management[73]. Corporate Governance - The financial report was approved by the board of directors on August 23, 2023[163]. - The financial statements are prepared based on the accounting standards issued by the Ministry of Finance, reflecting the company's financial position as of June 30, 2023[168]. - The company has not reported any significant changes in its debt levels, maintaining a consistent financial leverage ratio[152].

证券代码：000590 证券简称：启迪药业 公告编号：2023-045 启迪药业集团股份公司 启迪药业集团股份公司（以下简称"公司"）第十届监事会第二次会议通知 于 2023 年 8 月 11 日通过电子邮件的方式发出，会议于 2023 年 8 月 21 日以现场 结合通讯表决方式召开。会议应参加表决监事 3 人，实参加表决监事 3 人，其中 以通讯方式表决 1 人，无委托出席情况。符合有关法律、法规、规章和公司章程 的规定。会议审议如下事项： 一、审议通过《2023 年半年度报告》全文及摘要 审核意见如下：经审核，监事会认为董事会编制和审议公司 2023 年半年度 报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票赞成，0 票反对，0 票弃权 二、审议通过《2023 年半年度募集资金存放和使用情况的专项报告》 表决结果：3票赞成，0票反对，0票弃权。 第十届董事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 审核意见如下：经审核 ...

法定代表人：焦祺森 主管会计工作的负责人：唐婷 会计机构负责人：朱倩 汇总表第 1 页 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：启迪药业集团股份公司 单位：万元 | | | 占用方与上 | 上市公司核 | 年期初占 2023 | 年 2023 | 月占用 1-6 | | 年 2023 1-6 | 月 | 年 2023 1-6 | | 2023 年6 | 月 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 用资金余额 | | 累计发生金额（不 | | 占用资金的利 | | 月偿还累计 | | 30 号占用 | | 原因 | 占用性质 | | | | 联关系 | 目 | | | 含利息） | | 息(如有) | | 发生金额 | | 资金余额 | | | | | 控股股东、实际控 | | | | | | | | | | | | | ...

启迪药业集团股份公司 2023 年半年度募集资金存放和使用情况报告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：000590 证券简称：启迪药业 公告编号：2023-047 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证监会《关于核准启迪古汉集团股份有限公司非公开发行股票的批 复》（证监许可[2017]87 号）文件的核准，公司获准非公开发行不超过 1,614 万股新股。本次实际发行人民币普通股（A 股）16,140,000 股，发行价格为人民 币 17.76 元/股，募集资金总额为人民币 286,646,400.00 元，扣除发行费用后的 募集资金净额为人民币 278,696,400.00 元。 本次募集资金到账时间为 2017 年 5 月 2 日，募集资金到位情况已经天职国 际会计师事务所（特殊普通合伙）审验，并于 2017 年 5 月 3 日出具天职业字 [2017]12468 号验资报告。 （二）以前年度已使用金额、本年度使用金额及当前余额 截至 2023 年 6 月 30 日，公司累计使用募集资金人民币 200,93 ...

启迪药业集团股份公司 关于第十届董事会第二次会议相关事项的独立董事意见 根据中国证监会《上市公司独立董事规则》《上市公司治理准则》《深圳证券 交易所股票上市规则》《公司章程》等有关文件规定。我们作为公司的独立董事， 对公司第十届董事会第二次会议审议的相关事项发表如下独立意见： 一、关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项 说明和独立意见 依据《关于规范上市公司与关联方资金往来及上市公司对外担保若干问题的 通知》（证监会[2003]56号）、《关于规范上市公司对外担保行为的通知》（证监发 [2005]120号）及《公司章程》等相关文件规定，我们对控股股东及其他关联方 占用公司资金、公司对外担保情况发表如下意见： 公司报告期内不存在控股股东及其关联方对上市公司的非经营性占用资金 情况，也没有为控股股东及其他关联方提供担保的情形；截至 2023年6月30日， 公司为本公司控股子公司实际担保余额为0元。公司无逾期担保、无涉及诉讼的 担保。 二、2023 年半年度募集资金存放和使用情况的专项报告的独立意见 经审阅公司编制的《2023 年半年度募集资金存放与使用情况的专项报告》 及询问公司相关业务人员 ...

证券代码：000590 证券简称：启迪药业 公告编号：2023-044 启迪药业集团股份公司 第十届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 表决结果：7 票赞成，0 票反对，0 票弃权。 二、审议通过《2023年半年度募集资金存放和使用情况的专项报告》 具体内容详见同日刊载于《中国证券报》《证券时报》《上海证券报》和巨潮 资讯网（http://www.cninfo.com.cn）上的《2023 年半年度募集资金存放和使 用情况报告》。 表决结果：7 票赞成，0 票反对，0 票弃权。 二、审议通过《关于修订<内幕信息知情人管理制度>的议案》 根据《中华人民共和国证券法》《上市公司信息披露管理办法》《上市公司监 管指引第 5 号——上市公司内幕信息知情人登记管理制度》《深圳证券交易所股 票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等相关法律法规的最新要求，为进一步完善公司治理制度，对《内幕 启迪药业集团股份公司（以下简称"公司"）第十届董事会第二次会议通知 于 2023 年 8 月 11 ...

启迪药业集团股份公司 内幕信息知情人登记管理制度 （公司第十届董事会第二次会议审议通过） 1、总 则 1.1 为进一步规范启迪药业集团股份公司（以下简称"公司"）的内幕信息管理， 加强内幕信息保密工作，建立内幕信息知情人档案材料，以维护信息披露公平、公正原 则，保护投资者的合法权益，有效防范内幕交易等证券违法违规行为，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《深圳证券 交易所股票上市规则》《上市公司监管指引第5号——上市公司内幕信息知情人登记管理 制度》等有关法律、法规和《公司章程》《公司信息披露管理制度》的相关规定，制定 本制度。 1.2 本制度适用于公司各部门、控股子公司及公司能够对其实施重大影响的参股公 司。 2、内幕信息的含义与范围 2.1 本制度所指内幕信息，根据《证券法》相关规定，涉及公司的经营、财务或者 对公司股票交易价格有重大影响的尚未公开的信息。 尚未公开是指公司尚未在中国证券监督管理委员会（以下简称"中国证监会"）及 证券交易所指定的上市公司信息披露媒体公开披露的信息。 2.2 本制度所指内幕信息的范围包括但不限于： 2.2.1 公司的经营方针和经 ...

证券代码：000590 证券简称：启迪药业 公告编号：2023-043 启迪药业集团股份公司 关于募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证监会《关于核准启迪古汉集团股份有限公司非公开发行股票的批 复》（证监许可[2017]87 号）文件的核准，公司获准非公开发行不超过 1,614 万股新股。本次实际发行人民币普通股（A 股）16,140,000 股，发行价格为人民 币 17.76 元/股，募集资金总额为人民币 286,646,400.00 元，扣除发行费用后的 募集资金净额为人民币 278,696,400.00 元。 公司已按照《中华人民共和国公司法》、《中华人民共和国证券法》、《上 市公司证券发行管理办法》、《深圳证券交易所股票上市规则》、《上市公司监 管指引第2号-上市公司募集资金管理和使用的监管要求》等相关规定的要求制定 并修订了《公司募集资金管理办法》（以下简称"《管理办法》"），对募集资 金实行专户存储制度，对募集资金的存放、使用、项目实施管理、投资项目的变 更及使用情况的监督等进行了 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥101,199,883.45, representing a 10.76% increase compared to ¥91,371,093.42 in the same period last year[5] - Net profit attributable to shareholders decreased by 47.33% to ¥6,584,800.39 from ¥12,501,913.58 year-on-year[5] - Basic and diluted earnings per share both fell by 47.32% to ¥0.0275 from ¥0.0522 in the same period last year[5] - In Q1 2023, the company's net profit was CNY 6,608,510.61, a decrease of 46.9% compared to CNY 12,450,763.04 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 8,275,180.58, down 44.1% from CNY 14,824,181.88 in the same period last year[18] - Total revenue from operating activities was CNY 71,177,372.95, a decline of 8.8% compared to CNY 78,919,381.36 in Q1 2022[19] Cash Flow - The net cash flow from operating activities was -¥71,412,078.80, a decline of 87.61% compared to -¥38,063,764.03 in the previous year[5] - The company reported a net cash outflow from operating activities of CNY -71,412,078.80, worsening from CNY -38,063,764.03 in the previous year[19] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 181,835,488.02, compared to CNY 119,572,132.68 at the end of Q1 2022[20] - The company's cash flow from financing activities increased significantly by 1312.92% to ¥18,670,529.41, primarily due to new bank loans[9] - The company’s financing activities generated a net cash inflow of CNY 18,670,529.41, compared to CNY 1,321,413.90 in the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,160,864,614.18, a decrease of 0.50% from ¥1,166,753,854.92 at the end of the previous year[5] - Total assets as of March 31, 2023, were ¥1,160,864,614.18, down from ¥1,166,753,854.92 at the beginning of the year, a decrease of 0.5%[16] - Total liabilities decreased to ¥451,762,232.36 from ¥464,259,983.71, a decline of 2.7%[16] - The company's equity attributable to shareholders increased by 0.94% to ¥705,053,220.37 from ¥698,468,419.98 at the end of the previous year[5] Expenses - Total operating costs for Q1 2023 were ¥94,851,970.71, up 21.2% from ¥78,324,425.75 in Q1 2022[17] - The company recorded a net loss from operating activities, with a significant increase in expenses leading to a net profit decline of 46.92%[9] - Research and development expenses increased to CNY 3,035,083.94, up from CNY 2,678,282.04 in the previous year, reflecting a focus on innovation[18] - The company recorded a significant decrease in sales expenses, which rose to CNY 22,923,928.51 from CNY 15,070,557.79, indicating increased investment in marketing[18] - The company's financial expenses included interest expenses of CNY 1,051,034.62, compared to CNY 96,635.60 in the previous year, highlighting increased borrowing costs[18] Receivables and Inventory - The company's receivables financing increased by 60.89% to ¥86,750,573.95, mainly due to an increase in received bills[8] - The company reported a significant increase in accounts receivable financing to ¥86,750,573.95 from ¥53,920,546.58, an increase of 60.9%[15] - Accounts receivable decreased to ¥18,867,109.01 from ¥24,369,559.97, a reduction of 22.6%[15] - Inventory increased to ¥133,364,483.70 from ¥118,222,841.95, reflecting a growth of 12.8%[15] Shareholder Information - The number of major shareholders includes启迪科技服务有限公司 with 70,432,904 shares, representing a significant portion of the company's equity[12]

股票代码：000590 股票简称：启迪药业 启迪药业集团股份公司投资者关系活动记录表 编号：2023-001 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 员姓名 线上参与启迪药业 2022 年度网上业绩说明会的投资者 时间 2023 年 04 月 14 日（星期五）下午 15:00-17:00 地点 "启迪药业投资者关系"微信小程序 上市公司接待人员 姓名 董事、总裁：冯雪先生 董事、副总裁、财务总监：唐婷女士 副总裁、董事会秘书：曹定兴先生 独立董事：龙小明先生 投资者关系活动主 要内容介绍 1、问：请问一下股票价格为什么不高？ 答：尊敬的投资者您好，二级市场的股价表现是多种因 素综合作用的结果。公司将继续努力推动公司高质量发 展，聚焦行业发展，通过创新驱动，品牌驱动，资本驱 动做大做强公司业绩与市值规模，为消费市场提供品质 过硬的品牌产品，为资本市场创造更有投资价值的上市 公司。感谢您对公司的关心和关注。 2、问：古汉养生精在改善老年痴呆等老年退行性疾病 等方面的研究进程？ 答：尊 ...